

Mobile Gene officially enters the European precision medicine market

07 July 2021 | News

Acquires MC Diagnostics, a professional medical molecular diagnostic company in the UK



Hong Kong-based Mobile Gene Biotechnology Co., Ltd. has recently completed the acquisition of MC Diagnostics Ltd. (MCD).

MCD is a professional medical molecular diagnostic company headquartered in the United Kingdom. This acquisition marks ActionGene's official entry into the European precision medicine market.

MCD was established in 2006 and mainly provides automated multi-molecule detection and customized image integration analysis. MCD's Automated Low Density Array System ("ALDAS") has now provided reliable clinical analysis applications in the field of HLA typing and blood typing system diagnosis.

There is a huge demand for clinical cancer diagnostic tools with high sensitivity, short detection time and relatively affordable prices. Acting genes are the pioneers of Next Generation Sequencing (NGS). Cooperating with MCD to develop a fusion gene detection chip on the ALDAS platform, a significant breakthrough has been made recently. Fusion gene detection can be carried out simply and automatically, and has a high degree of consistency with NGS detection. The first gene chip-ACTSpot™ NTRK test will be launched in August this year.

Acting Gene is a professional NGS testing company and a pioneer in Asian tumor molecular diagnostics. This acquisition not only allows Acting Gene to seize the world's leading position in the development and application of gene chips, but also demonstrates the diversification and globalization of the group. Business strategy.